Özet:

Objective: To investigate the visual acuity and anatomical outcomes of intravitreal aflibercept treatment in patients with diabetic macular edema (DME) who were unresponsive to ranibizumab. Methods: Patients with refractory DME treated with at least 3 consecutive injections of ranibizumab, 4-6 weeks apart, before switch and with at least 2 aflibercept injections after that in the period of May 2013 to October 2017 were considered eligible for study participation. “The patients” demographic characteristics, best-corrected visual acuity (BCVA), and central foveal thickness (CFT) were recorded at baseline, pre-switch, the first month post-switch, and the final visit. Results: A total of 33 eyes of 28 patients were investigated. The average number of ranibizumab injections before switching to aflibercept was 4.97±1.94 and that of the subsequent aflibercept injections was 2.54±0.6. The mean baseline BCVA was 0.56 ± 0.38 logMAR. After the switch, the BCVA during the first and final visits was 0.41±0.34 logMAR (p=0.19) and 0.36±0.34 (p=0.16), respectively. After switching, clinical follow-up data for at least 6 months were available for all eyes. The mean baseline CFT was 504±123.7 μm (264-844 μm).One month after the switch, the average CFT had significantly reduced to 338.8±105.3 μm (225-615 μm) (p=0.0001). At the final visit, the average CFT was 345.7±137.4 μm (136-892 μm) (p=0.0002). Before and after the switch, the mean intraocular pressure (IOP) was 14.18±3.66 mmHg and 13.54±3.81 mmHg respectively (p=0.46). Conclusion: Switch to aflibercept from ranibizumab in patients with recalcitrant DME resulted in significant anatomical improvements. Although the BCVA increased and the IOP decreased, these changes were not statistically significant.

Anahtar Kelimeler: